Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly announced an agreement to acquire privately held Disarm Therapeutics to expand its efforts to develop treatments for neurological diseases including ALS and MS; LLY stock fell. The post Eli Lilly Acquisition Expands Efforts To Treat Neurological Diseases appeared first on Investor's Business Daily.

Eli Lilly Acquisition Expands Efforts To Treat Neurological Diseases

ALPS Barron's 400 ETF

Trns DS S&P 500 Shs

iShares Core High Dividend ETF

iShares S&P 500 Value ETF

Johnson & Johnson

iShares MSCI USA Quality Factor ETF

Invesco S&P 500 Quality ETF

Invesco S&P 500 Low Volatility ETF

SPDR Portfolio S&P 500 High Dividend ETF

iShares Edge MSCI Min Vol USA ETF

iShares MSCI USA Value Factor ETF

Vanguard Value ETF

Vanguard High Dividend Yield ETF

Volatility has once again been playing foul in the stock market due to resurgent COVID-19 infections and fading hopes of additional stimulus. Investors should follow some techniques to minimize volatility in their portfolio.

Pandemic Surges, Stimulus Fades: ETF Strategies to Follow

INDIANAPOLIS and CAMBRIDGE, Mass., Oct. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a definitive agreement to acquire Disarm Therapeutics, a privately-held biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal...

Lilly Announces Agreement to Acquire Disarm Therapeutics

LOS ANGELES--(BUSINESS WIRE)---- $LLY #LLY--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Eli Lilly and Company

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Eli Lilly and Company and Encourages Investors with Losses of $100,000 to Contact the Firm

Market indexes closed lower for their second-straight session, following a string of four days in a row higher.

Stocks Down 2nd Straight Day: Prime, Lilly, United Q3 & More

LOS ANGELES--(BUSINESS WIRE)---- $LLY #classaction--The Law Offices of Frank R. Cruz announces an investigation of Eli Lilly and Company (“Eli Lilly” or the “Company”) (NYSE: LLY) on behalf of investors concerning the Company’s possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. In August 2020, the Company began a clinical trial to test whether adding the Company's antibody-based drug, LY-CoV555, to remdesivir would benefit patients diagnosed with

The Law Offices of Frank R. Cruz Announces Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)---- $LLY #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $LLY #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

FDA inspectors last year noted issues at a manufacturing site now being used to produce the monoclonal antibody LY-CoV555.

Eli Lilly's COVID-19 Treatment Candidate Has a Manufacturing Site Problem

The National Institutes of Health put the brakes on the study in what the drugmaker calls "an abundance of caution."

Eli Lilly Coronavirus Antibody Drug Trial Paused

Eli Lilly (LLY) shareholders are hitting the exits after reports raised questions about the company's COVID-19 candidate.

Eli Lilly (LLY) Selling Off After Safety Disclosures

Lilly (LLY) is developing antibody candidates for a potential COVID-19 treatment in several clinical studies.

Lilly's Coronavirus Antibody Study Paused on Safety Concerns

The feds found serious quality-control lapses at a New Jersey factory where Eli Lilly & Co. plans to produce its antibody treatment for COVID-19, a new report says. Food and Drug Administration officials who spent 10 days inspecting the drugmaker’s Branchburg plant last November discovered that data on the facility’s manufacturing processes had been deleted.

FDA reportedly found quality-control lapses at Eli Lilly plant making COVID-19 drug

Shares of Eli Lilly & Co. were down 0.5% in premarket trading on Wednesday, the day after the drug maker confirmed that a clinical trial for its COVID-19 antibody treatment in combination with remdesivir had been paused. Gilead Sciences Inc. received emergency authorization for remdesivir in May as a COVID-19 therapeutic.

NIH confirms trial for Lilly antibody treatment is paused

There's more good news than bad for the big drugmaker.

Late-Stage Study of Lilly's COVID-19 Antibody Therapy Paused: Buy the Stock on the Dip?

The Eli Lilly And Co (NYSE: LLY) plant being readied to make an antibody therapy for COVID-19 has been found to have serious quality control problems by the United States Food and Drug Administration, Reuters reported Tuesday. What Happened: As per government documents, two inspectors who visited the drugmaker’s Branchburg, New Jersey plant last November, found that data on various manufacturing processes had been deleted and not audited properly.

Eli Lily COVID-19 Antibody Therapy Plant Has Serious Quality Control Issues, FDA Finds: Report

"It's kind of paradoxical, but actually it's reassuring" to see coronavirus drug trials paused when safety concerns arise, former CDC Director Dr. Tom Frieden told CNBC.

Ex-CDC director: Pauses to coronavirus drug trials give 'reassurance' that corners aren't being cut

In the race to get COVID-19 treatment options to market, Eli Lilly is the latest to suffer a setback. What Happened: The New York Times reports Eli Lilly and Co (NYSE: LLY) paused its Phase 3 clinical trial for the ACTIV-3 antibody treatment.

Eli Lilly Halts Antibody COVID-19 Trial

President Trump has promoted the company’s antibody treatment in recent videos.

Eli Lilly Covid-19 Antibody Treatment Trial Is Paused Due To 'Potential Safety Concern'

Eli Lilly (LLY) on Tuesday confirmed it's halted final-stage testing of its Covid-19 treatment candidate on potential safety concerns by U.S. health regulators, and LLY stock fell.

Eli Lilly Pauses Covid-19 Treatment Clinical Trials Over Safety Concerns

Shares of Eli Lilly & Co. tumbled 3.1% in trading on Tuesday after the drug maker confirmed a data safety monitoring board had paused enrollment in a clinical study testing its experimental COVID-19 monoclonal antibody treatment in combination with Gilead Sciences Inc.'s remdesivir. "Safety is of the utmost importance," a company spokesperson said in an email.

A study testing Lilly's antibody treatment and remdesivir is paused

U.S. drugmaker Eli Lilly and Co said on Tuesday that the government-sponsored clinical trial of its COVID-19 antibody treatment has been paused because of a safety concern.

Eli Lilly antibody trial paused due to potential safety concern

The ACTIV-3 monoclonal antibody trial - a phase three randomized controlled trial - has been paused due to potential safety concerns, Eli Lilly confirmed to CNBC.

U.S. pauses Eli Lilly's trial of a coronavirus antibody treatment over safety concerns

Eli Lilly's (LLY) mirikizumab continues to show symptom improvement and reduction of intestinal mucosal inflammation in Crohn's disease patients after a year-long treatment in a mid-stage study.

Lilly's Mirikizumab Retains Efficacy in Crohn's Disease Study

Apple

Alibaba

Canopy Growth

Cigna

UnitedHealth Group

Walgreens

Investors have these seven election stocks to consider avoiding, as uncertainties grow in the near-term and market selling rises. The post 7 Elections Stocks You Definitely Want To Avoid Leading up To the Big Vote appeared first on InvestorPlace.

News for Eli Lilly Stock (LLY)